Cingulate to Participate in Benzinga All Live Access Event
April 14, 2023 14:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., April 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
TILT Holdings Announces April Conference Schedule
April 04, 2023 07:30 ET
|
TILT Holdings Inc.
PHOENIX, April 04, 2023 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT” or the “Company”) (NEO: TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation...
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
April 04, 2023 06:45 ET
|
Cingulate Inc.
Trial On Track for 3Q 2023 Results Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
Mobiquity Technologies Unveils ATOS 2.0: A New and Improved Privacy-Centric Advertising Platform
March 23, 2023 08:30 ET
|
Mobiquity Technologies, Inc.
NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Mobiquity Technologies, Inc. (NASDAQ: MOBQ) (the “Company”), a leading provider of next-generation data intelligence and advertising technologies,...
Mobiquity Adds Industry Veteran, Brett Perloff, to Head-Up Revenue in Anticipation of New Product Launch
March 16, 2023 08:30 ET
|
Mobiquity Technologies, Inc.
NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- Mobiquity Technologies, Inc. (NASDAQ: MOBQ) (the “Company”), a leading provider of next-generation data intelligence and advertising technologies, today...
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
March 13, 2023 06:45 ET
|
Cingulate Inc.
Go-to-Market Solution Provides Full Commercial Support for the First, True Entire Active-Day Medication Designed to treat ADHD Indegene Model Geared for Efficient National Commercial Launch in...
Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
March 10, 2023 16:05 ET
|
Cingulate Inc.
CTx-1301 Phase 3 Adult Dose-Optimization Study Ongoing; Results Expected 3Q 2023 Positive Top-Line Data from CTx-1301 Fed/Fast Study Announced, Full Results Submitted for Presentation at Forthcoming...
Mobiquity Technologies Launches Mobi-AI Engine for Digital Advertising
March 01, 2023 08:45 ET
|
Mobiquity Technologies, Inc.
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Mobiquity Technologies, Inc. (NASDAQ: MOBQ) (the “Company”), a leading provider of next-generation data intelligence and advertising technologies, has...
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
February 23, 2023 16:30 ET
|
Cingulate Inc.
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., Feb. 23, 2023 (GLOBE NEWSWIRE) --...
SGLY Class Action Deadline Alert: Johnson Fistel Encourages Shareholders to Submit Their Losses
January 10, 2023 07:54 ET
|
Johnson Fistel, LLP
SAN DIEGO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Singularity Future...